September 2016—Great Basin Scientific announced that its Shiga Toxin Direct Test received CE marking under the European directive on in vitro diagnostic medical devices. The test is now qualified for distribution in more than 32 countries across Europe.
Read More »Multiplex Staph blood culture panel cleared, 5/16
May 2016—Great Basin Scientific has received FDA clearance for its Staph ID/R Blood Culture Panel. The panel is a sample-to-result, automated, DNA multiplex assay for simultaneous identification of Staphylococcus aureus and Staphylococcus species directly from positive blood cultures.
Read More »Group B strep test receives 510(k) clearance, 8/15
Great Basin Scientific announced the FDA clearance and commercial availability of its molecular diagnostic test for group B streptococcus. The group B strep assay provides accurate results in approximately 90 minutes with a specimen from enriched LIM broth. By targeting a highly conserved region of the cfb (CAMP factor) gene, the molecular assay provides definitive identification and a more rapid diagnosis of the mother’s GBS colonization status compared to standard culture-based tests, which may take up to an additional 48 hours.
Read More »Great Basin secures $9.5 million in funding, 3/13
March 2013—Great Basin Corp., a privately held molecular diagnostics company that develops sample-to-result solutions, has raised $9.5 million in series B funding. The funding was led by private investors and will be used to expand manufacturing, fund research and development, and expand global commercialization efforts.
Read More »